Jerry Bagel, MD, MS, and Brett King, MD, PhD, provide an overview of JAK inhibitors and their mechanisms of action in dermatology care.

Experts in dermatology review currently available JAK inhibitors for use in patients with dermatological conditions and highlight their differences.

Drs Jerry Bagel and Brett King discuss safety considerations and the clinical impact of how boxed warnings for JAK inhibitors highlighting how they affect physician decision-making.

Jerry Bagel, MD, MS, and Brett King, MD, PhD, explore how severity of disease factors into treatment selection regarding the use of JAK inhibitors.

Brett King, MD, PhD, shares insight on the dosage efficacy of oral JAK inhibitors abrocitinib and upadacitinib in atopic dermatitis.

Jerry Bagel, MD, MS, and Brett King, MD, PhD, discuss the use of topical JAK inhibitors in alopecia areata, vitiligo, and atopic dermatitis.

Dermatology experts discuss clinical specifics of JAK [Janus kinase] inhibitors and their impact on the treatment of patients with vitiligo and alopecia areata.

Jerry Bagel, MD, MS, and Brett King, MD, PhD, consider how new advances in oral medication will impact physicians’ and patients’ decision-making when it comes to treatment of alopecia areata, vitiligo, and atopic dermatitis.

Experts in dermatology review how JAK inhibitors will impact dermatology care across the board.